Linda De Vooght: Between the Pipette and the Patient - IMI AMR Accelerator

Read the full interview 👉 amr-accelerator.eu/news/intervi...

✨ We're excited to introduce Linda De Vooght — postdoctoral researcher at the RespiriTB project and the newest face in our AMR Accelerator researcher spotlight series!
"Antibiotics should not be taken for granted. People are already dying from infections that are difficult or impossible to treat."

✨ We're excited to introduce Linda De Vooght — postdoctoral researcher at the RespiriTB project and the newest face in our AMR Accelerator researcher spotlight series!
"Antibiotics should not be taken for granted. People are already dying from infections that are difficult or impossible to treat."

Pooled analyses of Clostridioides difficile vaccine trials identify baseline predictors for vaccine response - Scientific Reports Clostridioides difficile (C. difficile) is a major cause of severe diarrhea and colitis usually affecting individuals with dysbiosis. Currently, there is no licensed vaccine nor prophylaxis for C. dif...

Link to the study:

www.nature.com/articles/s41...

📢 𝙅𝙪𝙨𝙩 𝙥𝙪𝙗𝙡𝙞𝙨𝙝𝙚𝙙!
𝗧𝗼𝘄𝗮𝗿𝗱𝘀 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗩𝗮𝗰𝗰𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗖. 𝗱𝗶𝗳𝗳𝗶𝗰𝗶𝗹𝗲 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻

Today we highlight a study by researchers from the COMBINE project published in Scientific Reports analysing data from over 1,000 participants across Phase II and III clinical trials of 𝘊𝘭𝘰𝘴𝘵𝘳𝘪𝘥𝘪𝘰𝘪𝘥𝘦𝘴 𝘥𝘪𝘧𝘧𝘪𝘤𝘪𝘭𝘦 vaccines.

Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries Tuberculosis (TB) is one of the deadliest infectious diseases in the world with more than a million people dying of TB each year. Accurate and timely TB diagnosis has the potential to alleviate the global TB burden; therefore, one of the pillars of the End TB Strategy developed by the World Health Organization (WHO) is the early diagnosis of TB, including universal drug-susceptibility testing (DST). The WHO emphasises the importance of DST before treatment initiation, using molecular WHO-recommended rapid diagnostic tests (mWRDs). Currently available mWRDs are nucleic acid amplification tests, line probe assays, whole genome sequencing, and targeted next-generation sequencing. However, implementing the sequencing mWRDs in routine laboratories in low-income countries is constrained by the existing infrastructure, high cost, the specialised skills needed, data storage, and the current delay in results compared with other routine methods. These limitations are pronounced in resource-limited settings, which often have a high TB burden and need for innovative TB diagnostic technologies. In this article we propose several possible solutions, like adapting infrastructure capacity to needs, advocating for lowering costs, building bioinformatics and laboratory capacity, and increasing the use of open-access resources for software and publications.

Link to the study (open access) 👇
publications.ersnet.org/content/brea...

𝗥𝗲𝘁𝗵𝗶𝗻𝗸𝗶𝗻𝗴 𝗧𝗕 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗶𝗻 𝗛𝗶𝗴𝗵-𝗕𝘂𝗿𝗱𝗲𝗻 𝗦𝗲𝘁𝘁𝗶𝗻𝗴𝘀

Today we highlight a study by researchers of UNITE4TB published in Breathe examining the implementation of molecular diagnostic tools for tuberculosis in resource-limited, high-burden countries.
𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

Maya Rima: Driven by Curiosity, Guided by Impact - IMI AMR Accelerator

Link to the interview: amr-accelerator.eu/news/intervi...

✨ Meet Maya Rima, early-career researcher in the RespiriNTM project and the latest voice in our AMR Accelerator researcher spotlight series!
We are grateful to Maya for sharing her journey, her insights, and her passion.
Find the the link to her interview in the first comment 👇

Our annual Cross Project Meeting of the IMI AMR Accelerator took place on 5 March at BioVersys AG in Basel — and it was a very productive one!
Representatives from all projects came together to present progress & discuss the plans ahead. It was great to see the breadth of work across the portfolio.

🫱🏼‍🫲🏻 We're proud to present the #PrIMAVeRaProject and our #perpetualobervationalstudies at the 7th @amr-accelerator.bsky.social Cross-Project Meeting held in Basel yesterday. We look forward to seeing everyone again at the PrIMAVeRa stakeholder meeting at #ESCMID2026!
@elskesieswerda.bsky.social

We’re live at the AMR Conference in Basel — come meet us today!

📍 Machine Learning for Gram-negative Permeability (Frederik Deroose)
📍 Improving Translational Pneumonia Models (Carina Vingsbo-Lundberg)

💬 Stop by the posters, say hello, and explore collaboration opportunities.

If you have data that could fit the open call, fill in this form to get in contact with the researchers: forms.office.com/e/YMs09w27ce

📢 Call for Data: Help Advance Antibiotic Discovery Against Gram-Negative Bacteria!

The AMR Accelerator Scientific Interest Group on Machine Learning is building a predictive model for membrane permeability in Gram-negative bacteria — and we need your support.
Link to the survey in first comment 👇

Meet us at the AMR Conference 2026! - IMI AMR Accelerator

Find out more about the research and the people behind it: amr-accelerator.eu/news/meet-us...

Meet us at the AMR Conference in Basel today and tomorrow!

🧠 Researchers from different projects of the accelerator are presenting posters on
Machine Learning for Gram-negative permeability
🧪 Advancing TB drug development with HFS-TB
🫁 The COMBINE Pneumonia Model

Will you be there? Get connected!

About us - IMI AMR Accelerator The AMR Accelerator is an IMI Programme that progresses the development of new medicines to treat or prevent resistant bacterial infections, aiming to deliver 10 preclinical or clinical candidates and...

For more infos on publications, tools & resources, project portfolios and a lot more, visit the AMR Accelerator website:
amr-accelerator.eu

Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome bc1 Complex | Antimicrobial Agents and Chemotherapy Drug-resistant tuberculosis is a global health care threat calling for novel effective treatment options. Here, we report on two novel cytochrome bc1 inhibitors (MJ-22 and B6) targeting the Mycobacterium tuberculosis respiratory chain with excellent intracellular activities in human macrophages. Both hit compounds revealed very low mutation frequencies and distinct cross-resistance patterns with other advanced cytochrome bc1 inhibitors.

Link to the study 👉 journals.asm.org/doi/10.1128/...

𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗧𝗕 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲

Today we highlight a study published by ERA4TB. It contributes to a growing pipeline of compounds designed to tackle drug-resistant TB through novel mechanisms and strategies.

𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

𝗥𝗲𝘃𝗶𝘀𝗶𝘁𝗶𝗻𝗴 𝗧𝗕 𝗣𝗵𝘆𝘀𝗶𝗼𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆
A study published by members of our project ERA4TB uncovers how 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 forms tightly biofilm-like cords that dramatically alter its interaction with the immune system.

𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

#amr #tuberculosis #antibiotics

Mechanopathology of biofilm-like Mycobacterium tuberculosis cords Energy storage in the cell membrane, made possible by the compression of cell surface lipids, enables individual Mycobacterium tuberculosis to grow into high-aspect-ratio mechanically resilient suprac...

Link to the study: www.cell.com/cell/fulltex...

Learn more about the AMR Accelerator on amr-accelerator.eu

𝗥𝗲𝘃𝗶𝘀𝗶𝘁𝗶𝗻𝗴 𝗧𝗕 𝗣𝗵𝘆𝘀𝗶𝗼𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆
A study published by members of our project ERA4TB uncovers how 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 forms tightly biofilm-like cords that dramatically alter its interaction with the immune system.

𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

#amr #tuberculosis #antibiotics

Hear from Marie Attwood (@reepkpd333.bsky.social) in an exclusive interview about her work in using 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 models in AMR research as a GNA NOW PK/PD expert.

She offers insights into:
🔬 Decade of progression
🧫 Hollow-fibre modelling
🦠 AI-driven discovery

🔗 https://bit.ly/4plTnqW

We are excited to share the latest work under RespiriTB, published in Nature Communications! The study explores how targeting the M. tuberculosis cytochrome bc1 complex could unlock new treatment options for both DS-TB & MDR-TB.

👉 https://go.nature.com/48cWgEV

How can we speed up TB clinical trials efficiently? Our latest work led by global TB experts, under UNITE4TB defines the ideal biomarker assays to reliably track treatment response, therefore helping trials be faster, smarter and more effective.

👉 Read at: https://bit.ly/4iVmPAu

𝗨𝗻𝗺𝗮𝘀𝗸𝗶𝗻𝗴 𝗛𝗼𝘀𝘁–𝗣𝗮𝘁𝗵𝗼𝗴𝗲𝗻 𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗧𝗕

Today we showcase a study by our project ERA4TB revealing a previously underappreciated mechanism by which 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 aggregates kill macrophages without being taken up by them.

𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

𝗨𝗻𝗺𝗮𝘀𝗸𝗶𝗻𝗴 𝗛𝗼𝘀𝘁–𝗣𝗮𝘁𝗵𝗼𝗴𝗲𝗻 𝗜𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗧𝗕

Today we showcase a study by our project ERA4TB revealing a previously underappreciated mechanism by which 𝘔𝘺𝘤𝘰𝘣𝘢𝘤𝘵𝘦𝘳𝘪𝘶𝘮 𝘵𝘶𝘣𝘦𝘳𝘤𝘶𝘭𝘰𝘴𝘪𝘴 aggregates kill macrophages without being taken up by them.

𝗪𝗵𝗮𝘁 𝗪𝗲 𝗗𝗶𝗱. 𝗪𝗵𝘆 𝗜𝘁 𝗠𝗮𝘁𝘁𝗲𝗿𝘀. 𝗪𝗵𝗲𝗿𝗲 𝗜𝘁 𝗟𝗲𝗮𝗱𝘀. 👇

Today is the International Day of Women and Girls in Science, and we're shining the spotlight on Ariane Bollack, who took part in the AMYPAD project as a PhD student. We asked her how taking part in the PPP shaped her career.

♀️ Today is the #InternationalDayofWomenandGirlsinScience! 🧠 Meet Ariane Bollack, a former PhD student from the AMYPAD project who's now working in industry. We asked her how the PPP shaped her career & what advice she has for young researchers 👉 link.europa.eu/K6GPPp
#WomenInScience #WomenInSTEM

In this latest study under @era4tb.bsky.social, researchers adopted physiologically‑based pharmacokinetic (PBPK) modelling and used a detailed computational model to project what those concentrations likely are in human lungs (both healthy and TB-infected).

👉 Read at: https://bit.ly/3KA2RQx

Hear from Pedro Quintela in an interview about his work in GNA NOW advancing 𝘪𝘯 𝘷𝘪𝘷𝘰 proof-of-concept models for AMR research.

He shares insights into:
🦠 Broader pathogen coverage
🤝 Interdisciplinary collaboration
💡 Championing the promise of each experiment

https://bit.ly/49Hdtr1